166 related articles for article (PubMed ID: 2033396)
1. A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy.
McQuaid A; Mason J
J Inorg Biochem; 1991 Feb; 41(2):87-92. PubMed ID: 2033396
[TBL] [Abstract][Full Text] [Related]
2. The interactions of penicillamine with copper in vivo and the effect on hepatic metallothionein levels and copper/zinc distribution: the implications for Wilson's disease and arthritis therapy.
McQuaid A; Lamand M; Mason J
J Lab Clin Med; 1992 Jun; 119(6):744-50. PubMed ID: 1593220
[TBL] [Abstract][Full Text] [Related]
3. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
4. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.
Purchase R
Sci Prog; 2013; 96(Pt 1):19-32. PubMed ID: 23738435
[TBL] [Abstract][Full Text] [Related]
5. Studies on the uptake and subsequent tissue distribution of [35S]trithiomolybdate in rats: effects on metallothionein copper in liver, kidney, and intestine.
Wang ZY; Mason J
J Inorg Biochem; 1988 May; 33(1):19-29. PubMed ID: 3379395
[TBL] [Abstract][Full Text] [Related]
6. The uptake and intracellular distribution of [35S]trithiomolybdate in bovine liver in vivo.
Wang ZY; Poole D; Mason J
J Inorg Biochem; 1987 Oct; 31(2):85-93. PubMed ID: 3430149
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model.
Lee DY; Brewer GJ; Wang YX
J Lab Clin Med; 1989 Dec; 114(6):639-45. PubMed ID: 2592854
[TBL] [Abstract][Full Text] [Related]
8. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
[TBL] [Abstract][Full Text] [Related]
9. The effect of trithiomolybdate and some selenium compounds upon 109Cd labeled rat metallothionein in vitro: the possibilities for cadmium chelation therapy.
Yuan WZ; Dong WH; Lamand M; Mason J
J Inorg Biochem; 1991 Nov; 44(3):219-27. PubMed ID: 1757787
[TBL] [Abstract][Full Text] [Related]
10. The effect of certain chelating compounds on the urinary excretion of copper by the rat: observations on their clinical significance.
Gibbs K; Walshe JM
Clin Sci Mol Med; 1977 Oct; 53(4):317-20. PubMed ID: 913055
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?
Schilsky ML
Curr Gastroenterol Rep; 2001 Feb; 3(1):54-9. PubMed ID: 11177695
[TBL] [Abstract][Full Text] [Related]
12. The effect of D-penicillamine on metallothionein mRNA levels and copper distribution in mouse hepatocytes.
McArdle HJ; Kyriakou P; Grimes A; Mercer JF; Danks DM
Chem Biol Interact; 1990; 75(3):315-24. PubMed ID: 2379260
[TBL] [Abstract][Full Text] [Related]
13. The development of cirrhosis in Wilson's disease.
Sternlieb I
Clin Gastroenterol; 1975 May; 4(2):367-79. PubMed ID: 1092490
[No Abstract] [Full Text] [Related]
14. Comparison of disposition behavior and de-coppering effect of triethylenetetramine in animal model for Wilson's disease (Long-Evans Cinnamon rat) with normal Wistar rat.
Iseki K; Kobayashi M; Ohba A; Miyazaki K; Li Y; Togashi Y; Takeichi N
Biopharm Drug Dispos; 1992 May; 13(4):273-83. PubMed ID: 1600113
[TBL] [Abstract][Full Text] [Related]
15. Thiotungstate-copper interactions II. The effects of tetrathiotungstate on systemic copper metabolism in normal and copper-treated rats.
McQuaid A; Lamand M; Mason J
J Inorg Biochem; 1994 Feb; 53(3):205-18. PubMed ID: 8133256
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine).
Dubois RS; Rodgerson DO; Hambidge KM
J Pediatr Gastroenterol Nutr; 1990 Jan; 10(1):77-81. PubMed ID: 2324883
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
18. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice.
Hoogenraad TU
Brain Dev; 2006 Apr; 28(3):141-6. PubMed ID: 16466879
[TBL] [Abstract][Full Text] [Related]
19. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease.
Siegemund R; Lössner J; Günther K; Kühn HJ; Bachmann H
Acta Neurol Scand; 1991 Jun; 83(6):364-6. PubMed ID: 1887758
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents.
Brewer GJ; Yuzbasiyan-Gurkan V; Johnson V; Dick RD; Wang Y
J Am Coll Nutr; 1993 Feb; 12(1):26-30. PubMed ID: 8440814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
